Key Segments:
By Product
-
Ozempic
-
Trulicity
-
Mounjaro
-
Wegovy
-
Rybelsus
-
Saxenda
-
Victoza
-
Zepbound
-
Other Products
By Application
-
Type 2 Diabetes Mellitus
-
Obesity
-
Others
By Route of Administration
-
Parenteral
-
Oral
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Others
Regional Coverage:
U.S.
-
Northeast
-
Midwest
-
South
-
West
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players in the U.S. GLP-1 Receptor Agonist Market include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Amgen Inc., AstraZeneca plc, and Merck & Co., Inc., among others.
Key opportunities include oral formulation launches, cardiometabolic label expansions, and continued domestic capacity investment easing supply constraints.
The market is driven by rising obesity and diabetes prevalence, expanding employer and commercial payer coverage, and growing telehealth prescribing access.
The Ozempic segment dominated the U.S. GLP-1 Receptor Agonist Market, accounting for approximately 33.70% share in 2025.
The South dominated the U.S. GLP-1 Receptor Agonist Market in 2025 with a 32.00% share, driven by higher regional prevalence and a large population base.
